focus -WSS

focus

author：comprehensive 2025-09-03 15:18:58 - browse：91863

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Merck CEO won’t testify in Senate, citing no expertise in drug prices

explore

entertainment

WSS

How Medicaid coverage policies for immigrants impact new moms

Startup Neumora takes a novel depression drug to Phase 3

Medicare has a new plan to address drug shortages

Rescued Australian man who was adrift 3 months in Pacific with dog 'grateful' to be alive

Wegovy leads to weight loss. Can it treat depression, too?

How generative AI ratchets up security threats for health systems

entertainment

focus

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

leisure time

Jerome Adams on the need for new antivirals for Covid

FDA moves to stop vape shops from selling Elf Bar, Esco Bars

Continuity nursing helped my family in our darkest PICU moments

Pancreatic cancer early detection could be helped by AI

After affirmative action ruling, medical educators look to 'holistic review'

EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

Psychedelics group wrestles with new pharma identity

Detailed data confirm benefits, risks of Eli Lilly's Alzheimer's drug

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Vertex non

entertainment

Whistleblower: Blue Cross Blue Shield evaded $170 million in taxes

Reconstructing family trees of blood cells may help predict disease

How Medicaid coverage policies for immigrants impact new moms

As digital health tech proliferates, a new institute aims to cut through hype

A public scorecard can help hold safety

Medicare Advantage insurers face 0.2% cut to 2025 payments

leisure time

explore

entertainment

focus